Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Ischemic Heart Disease

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 200 articles: HTML format

Single Articles

August 2026
1. LEE KK, Wereski R, Lowe D, O'Brien R, et al
   Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain.
   N Engl J Med. 2026 Aug 29. doi: 10.1056/NEJMoa2608903.
   PubMed     Abstract available
   
   
   
2. BISCAGLIA S, Erriquez A, Colaiori I, Hakeem A, et al
   Complete Revascularization Guided by Functional Coronary Angiography in STEMI.
   N Engl J Med. 2026 Aug 29. doi: 10.1056/NEJMoa2605373.
   PubMed     Abstract available
   
   
   
3. OMEROVIC E, Koul S, Andersson J, Ponten J, et al
   Prasugrel versus Ticagrelor in Acute Coronary Syndromes.
   N Engl J Med. 2026 Aug 29. doi: 10.1056/NEJMoa2609057.
   PubMed     Abstract available
   
   
   
4. GIBSON CM, Steg PG, Bahit MC, Al-Lamee R, et al
   Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.
   N Engl J Med. 2026 Aug 29. doi: 10.1056/NEJMoa2608717.
   PubMed     Abstract available
   
   
   
5. BYRNE RA
   The Emerging Role of Treatment Policy Implementation Trials in Acute Coronary Syndrome.
   N Engl J Med. 2026 Aug 29. doi: 10.1056/NEJMe2610678.
   PubMed    
   
   
   
6. ZOUNGAS S, Wolfe R, Moran C, Nicholls SJ, et al
   Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults.
   N Engl J Med. 2026 Aug 29. doi: 10.1056/NEJMoa2607314.
   PubMed     Abstract available
   
   
   
7. TAKAHASHI K, Kozuma K, Morino Y, Kashiwabara K, et al
   Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI.
   N Engl J Med. 2026 Aug 29. doi: 10.1056/NEJMoa2606997.
   PubMed     Abstract available
   
   
   July 2026
8. SKEITH L, Bates SM
   Sex Hormone Influences on Cardiovascular Risk. Reply.
   N Engl J Med. 2026;395:10.
   PubMed    
   
   
   
9. BONNET F, Vaduva P
   Sex Hormone Influences on Cardiovascular Risk.
   N Engl J Med. 2026;395:519-520.
   PubMed    
   
   
   
10. DOUXFILS J, Creinin MD, Foidart JM
    Sex Hormone Influences on Cardiovascular Risk.
    N Engl J Med. 2026;395:518-519.
    PubMed    
    
    
    
11. LEE YJ, Kim BK
    LDL Cholesterol Targeting in Cardiovascular Disease. Reply.
    N Engl J Med. 2026;395:516.
    PubMed    
    
    
    
12. CRAVEDI P, Ruggenenti PL, Remuzzi G
    LDL Cholesterol Targeting in Cardiovascular Disease.
    N Engl J Med. 2026;395:515-516.
    PubMed    
    
    
    
13. ZHU Q, Wang S
    LDL Cholesterol Targeting in Cardiovascular Disease.
    N Engl J Med. 2026;395:515.
    PubMed    
    
    
    
14. VAN TWIST DJL, Beeren J
    LDL Cholesterol Targeting in Cardiovascular Disease.
    N Engl J Med. 2026;395:514-515.
    PubMed    
    
    
    
15. HOWELL RR, Jones KW
    LDL Cholesterol Targeting in Cardiovascular Disease.
    N Engl J Med. 2026;395:514.
    PubMed    
    
    
    
16. MALLIDI J, Lotif A
    LDL Cholesterol Targeting in Cardiovascular Disease.
    N Engl J Med. 2026;395:513-514.
    PubMed    
    
    
    
17. TIAN J, Wang Z, Wang Y, Wang F, et al
    Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.
    N Engl J Med. 2026;395:233-242.
    PubMed     Abstract available
    
    
    
18. LOK CE, Polkinghorne KR, Tomlinson G
    Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. Reply.
    N Engl J Med. 2026;395:312.
    PubMed    
    
    
    
19. MARCHINI M, Trezzi M
    Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.
    N Engl J Med. 2026;395:311-312.
    PubMed    
    
    
    
20. ZHANG Z, He S
    Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.
    N Engl J Med. 2026;395:311.
    PubMed    
    
    
    
21. YAMANOUCHI M, Tominaga N, Yonaha T
    Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.
    N Engl J Med. 2026;395:311.
    PubMed    
    
    
    
22. PARK KW, Kang J
    Balancing the Scales - Extended DAPT in Coronary Artery Disease.
    N Engl J Med. 2026;395:304-305.
    PubMed    
    
    
    
23. FEARON WF, Jeremias A, Witberg G, Al-Lamee R, et al
    Angiography-Derived Fractional Flow Reserve to Guide PCI.
    N Engl J Med. 2026;395:9-19.
    PubMed     Abstract available
    
    
    
24. RANDLES A
    Physiological Assessment of Coronary Artery Disease.
    N Engl J Med. 2026;395:80-83.
    PubMed    
    
    
    June 2026
25. 
    Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.
    N Engl J Med. 2026;394:2488.
    PubMed    
    
    
    
26. CHOI KH, Kang D, Hahn JY
    Stopping Beta-Blockers after Myocardial Infarction. Reply.
    N Engl J Med. 2026;394:2485-2486.
    PubMed    
    
    
    
27. WU W, Xu G, Gao X
    Stopping Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:2485.
    PubMed    
    
    
    
28. MESSERLI FH, Maqsood MH, Bangalore S
    Stopping Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:2484-2485.
    PubMed    
    
    
    
29. PIVATO CA, Pensato U, Stefanini GG
    Stopping Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:2484.
    PubMed    
    
    
    
30. VIGNATI C, Galotta A, Pezzuto B
    Stopping Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:2483-2484.
    PubMed    
    
    
    
31. DILETTI R, Daemen J, Faurie B, Barbierato M, et al
    Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI.
    N Engl J Med. 2026;394:2200-2211.
    PubMed     Abstract available
    
    
    May 2026
32. BIOLA H, Davis J, Khan SS, Lloyd-Jones D, et al
    Cardiovascular Risk Factors - Lifestyle Modifications.
    N Engl J Med. 2026;394:e44.
    PubMed    
    
    
    
33. VAFAI SB, Taubel J, Ashdown T, Patel RS, et al
    In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.
    N Engl J Med. 2026 May 25. doi: 10.1056/NEJMoa2601283.
    PubMed     Abstract available
    
    
    
34. BIOLA H, Khan SS, Lloyd-Jones D, Pagidipati NJ, et al
    Cardiovascular Risk Factors - Hypertension.
    N Engl J Med. 2026 May 20. doi: 10.1056/NEJMp2516850.
    PubMed    
    
    
    
35. SCHUNKERT H, Natarajan P, Samani NJ
    The Inherited Basis of Coronary Artery Disease. Reply.
    N Engl J Med. 2026;394:1967-1968.
    PubMed    
    
    
    
36. HINGORANI AD, Wald NJ
    The Inherited Basis of Coronary Artery Disease.
    N Engl J Med. 2026;394:1966-1967.
    PubMed    
    
    
    
37. LEE SJ, Yu HT, Kim JS
    Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents. Reply.
    N Engl J Med. 2026;394:1965-1966.
    PubMed    
    
    
    
38. FAUCHIER L, Guglieri M
    Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
    N Engl J Med. 2026;394:1964-1965.
    PubMed    
    
    
    
39. CACOULIDIS C
    Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
    N Engl J Med. 2026;394:1964.
    PubMed    
    
    
    April 2026
40. IBANEZ B, Jernberg T, Atar D
    Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. Reply.
    N Engl J Med. 2026;394:1660-1661.
    PubMed    
    
    
    
41. OMEROVIC E
    Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
    N Engl J Med. 2026;394:1660.
    PubMed    
    
    
    
42. TURGEON R
    Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
    N Engl J Med. 2026;394:1659-1660.
    PubMed    
    
    
    
43. BOHULA EA, Giugliano RP, Sabatine MS
    Evolocumab for Primary Prevention of Cardiovascular Disease. Reply.
    N Engl J Med. 2026;394:1658-1659.
    PubMed    
    
    
    
44. BUDOFF MJ, Iskander B
    Evolocumab for Primary Prevention of Cardiovascular Disease.
    N Engl J Med. 2026;394:1658.
    PubMed    
    
    
    
45. GARCIA DE TENA J, Morales-Ortega A, Bernal-Bello D
    Evolocumab for Primary Prevention of Cardiovascular Disease.
    N Engl J Med. 2026;394:1658.
    PubMed    
    
    
    
46. KJELDSEN SE, Kreutz R, Mancia G
    Evolocumab for Primary Prevention of Cardiovascular Disease.
    N Engl J Med. 2026;394:1657-1658.
    PubMed    
    
    
    
47. PIRIS GONZALEZ M, Ortiz A
    Evolocumab for Primary Prevention of Cardiovascular Disease.
    N Engl J Med. 2026;394:1656-1657.
    PubMed    
    
    
    
48. LIN S, He Y, He L, Liu Y, et al
    Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease.
    N Engl J Med. 2026;394:1480-1490.
    PubMed     Abstract available
    
    
    
49. SHARMA M, Dong Q, Hirano T, Kasner SE, et al
    Asundexian for Secondary Stroke Prevention.
    N Engl J Med. 2026;394:1467-1479.
    PubMed     Abstract available
    
    
    
50. NICHOLLS SJ, Pavo I, D'Alessio D
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. Reply.
    N Engl J Med. 2026;394:10.
    PubMed    
    
    
    
51. ANKER MS, Butler J, Anker SD
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1551-1553.
    PubMed    
    
    
    
52. XU H, Cong X, Lin L
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1551.
    PubMed    
    
    
    
53. VAN BRUGGEN F
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1551.
    PubMed    
    
    
    
54. BECATTINI C, Agnelli G, Paciaroni M
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1550-1551.
    PubMed    
    
    
    
55. CHUAN F, Gao Y, Zhou B
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1550.
    PubMed    
    
    
    
56. SKEITH L, Bates SM
    Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk.
    N Engl J Med. 2026;394:1514-1528.
    PubMed     Abstract available
    
    
    
57. CHOI KH, Kang D, Kim W, Doh JH, et al
    Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.
    N Engl J Med. 2026;394:1302-1312.
    PubMed     Abstract available
    
    
    March 2026
58. TESTA L, De la Torre Hernandez JM, De Maria GL, Jones DA, et al
    IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease.
    N Engl J Med. 2026 Mar 30. doi: 10.1056/NEJMoa2600440.
    PubMed     Abstract available
    
    
    
59. WELT F
    Seeing the Left Main Coronary Artery Clearly - Is IVUS Always Necessary?
    N Engl J Med. 2026 Mar 30. doi: 10.1056/NEJMe2602959.
    PubMed    
    
    
    
60. DAEMEN J, van der Eijk JA, Barbierato M, Byrne RA, et al
    Angiography-Based Physiology to Guide Coronary Revascularization.
    N Engl J Med. 2026 Mar 29. doi: 10.1056/NEJMoa2601841.
    PubMed     Abstract available
    
    
    
61. PERERA D, Ryan M, Ezad SM, Khan SQ, et al
    Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention.
    N Engl J Med. 2026 Mar 29. doi: 10.1056/NEJMoa2515704.
    PubMed     Abstract available
    
    
    
62. LEE YJ, Lee SJ, Kim JW, Lee SH, et al
    Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.
    N Engl J Med. 2026 Mar 28. doi: 10.1056/NEJMoa2600283.
    PubMed     Abstract available
    
    
    
63. GUIMARAES PO, Franken M, Lemos PA
    Aspirin after PCI in Acute Coronary Syndromes. Reply.
    N Engl J Med. 2026;394:1036-1037.
    PubMed    
    
    
    
64. CHAN SCH
    Aspirin after PCI in Acute Coronary Syndromes.
    N Engl J Med. 2026;394:1036.
    PubMed    
    
    
    
65. LI M, Zhang G, Liu X
    Aspirin after PCI in Acute Coronary Syndromes.
    N Engl J Med. 2026;394:1035-1036.
    PubMed    
    
    
    
66. STRASSMEIR ML, Baumer U, Niessner A
    Aspirin after PCI in Acute Coronary Syndromes.
    N Engl J Med. 2026;394:1035.
    PubMed    
    
    
    
67. FEARON WF
    Assessing Nonculprit Coronary-Artery Lesions in STEMI.
    N Engl J Med. 2026;394:1021-1022.
    PubMed    
    
    
    February 2026
68. CEREDA A, Stracqualursi M, Lucreziotti S
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:821-822.
    PubMed    
    
    
    
69. MUNKHAUGEN J, Atar D, Prescott E
    Beta-Blockers after Myocardial Infarction. Reply.
    N Engl J Med. 2026;394:824-825.
    PubMed    
    
    
    
70. IBANEZ B, Latini R, Rossello X
    Beta-Blockers after Myocardial Infarction. Reply.
    N Engl J Med. 2026;394:823-824.
    PubMed    
    
    
    
71. ZIEMINSKI JJ, Bell MR
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:822-823.
    PubMed    
    
    
    
72. GAMARDELLA M, Ciconte G, Pappone C
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:822.
    PubMed    
    
    
    
73. LLOP D, Turu M, Llop C
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:821.
    PubMed    
    
    
    
74. CHI KY, Mangalesh S, Nanna MG
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:820-821.
    PubMed    
    
    
    
75. RAHHAL A, Al Hijji M, Arabi AR
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:820.
    PubMed    
    
    
    
76. LIP GYH, Kuzma L
    Thromboprophylaxis for Atrial Fibrillation in Patients with Drug-Eluting Stents.
    N Engl J Med. 2026;394:713-715.
    PubMed    
    
    
    
77. LUSCHER TF, Wenzl FA
    Beta-Blockers after Myocardial Infarction - Toward Personalized Management.
    N Engl J Med. 2026;394:599-602.
    PubMed    
    
    
    
78. SCHUNKERT H, Natarajan P, Samani NJ
    The Inherited Basis of Coronary Artery Disease.
    N Engl J Med. 2026;394:576-587.
    PubMed     Abstract available
    
    
    January 2026
79. RYAN SJ, Jorstad OK, Skjelland M, Pesonen M, et al
    A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion.
    N Engl J Med. 2026;394:442-450.
    PubMed     Abstract available
    
    
    
80. THIELE H, Hassager C
    Cardiogenic Shock.
    N Engl J Med. 2026;394:62-77.
    PubMed     Abstract available
    
    
    December 2025
81. NICHOLLS SJ, Pavo I, Bhatt DL, Buse JB, et al
    Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
    N Engl J Med. 2025;393:2409-2420.
    PubMed     Abstract available
    
    
    November 2025
82. LEOPOLD JA
    Discontinuation of Aspirin in Acute Coronary Syndromes Treated with Coronary-Artery Stents.
    N Engl J Med. 2025;393:2164-2166.
    PubMed    
    
    
    
83. KRISTENSEN AMD, Rossello X, Atar D, Yndigegn T, et al
    Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
    N Engl J Med. 2025 Nov 9. doi: 10.1056/NEJMoa2512686.
    PubMed     Abstract available
    
    
    
84. BOHULA EA, Marston NA, Bhatia AK, De Ferrari GM, et al
    Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
    N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2514428.
    PubMed     Abstract available
    
    
    
85. LEE SJ, Yu HT, Lee YJ, Lee SH, et al
    Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
    N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2512091.
    PubMed     Abstract available
    
    
    
86. LOK CE, Farkouh M, Hemmelgarn BR, Moist LM, et al
    Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.
    N Engl J Med. 2025 Nov 7. doi: 10.1056/NEJMoa2513032.
    PubMed     Abstract available
    
    
    October 2025
87. NIJVELDT R, Maeng M, Beijnink CWH, Piek JJ, et al
    Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.
    N Engl J Med. 2025 Oct 28. doi: 10.1056/NEJMoa2512918.
    PubMed     Abstract available
    
    
    September 2025
88. MAGNUSSEN C, Lorenz T, Blankenberg S
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates. Reply.
    N Engl J Med. 2025;393:1247-1248.
    PubMed    
    
    
    
89. CORDERO L, Abasheva D, Ortiz A
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025;393:1246-1247.
    PubMed    
    
    
    
90. AKBARPOUR S, Azizpour Y, Larijani B
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025;393:1246.
    PubMed    
    
    
    
91. ZHENG X, Zhang J, Li Z
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025;393:1245-1246.
    PubMed    
    
    
    
92. COOPER KH
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025;393:1245.
    PubMed    
    
    
    
93. NICHOLLS SJ, Nelson AJ, Ray KK
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. Reply.
    N Engl J Med. 2025;393:928.
    PubMed    
    
    
    
94. GUO M, Liu Z
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025;393:927-928.
    PubMed    
    
    
    
95. ZHANG D, Wu H, Gong S
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025;393:927.
    PubMed    
    
    
    
96. MODARRESSI T
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025;393:926-927.
    PubMed    
    
    
    
97. JEPPSSON A, James S, Moller CH, Malm CJ, et al
    Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.
    N Engl J Med. 2025 Sep 1. doi: 10.1056/NEJMoa2508026.
    PubMed     Abstract available
    
    
    August 2025
98. TARANTINI G, Honton B, Paradies V, Lemesle G, et al
    Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction.
    N Engl J Med. 2025 Aug 31. doi: 10.1056/NEJMoa2508808.
    PubMed     Abstract available
    
    
    
99. LEMESLE G, Didier R, Steg PG, Simon T, et al
    Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.
    N Engl J Med. 2025 Aug 31. doi: 10.1056/NEJMoa2507532.
    PubMed     Abstract available
    
    
    
100. GUIMARAES PO, Franken M, Tavares CAM, Antunes MO, et al
     Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.
     N Engl J Med. 2025 Aug 31. doi: 10.1056/NEJMoa2507980.
     PubMed     Abstract available
     
     
     
101. MUNKHAUGEN J, Kristensen AMD, Halvorsen S, Holmager T, et al
     Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.
     N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2505985.
     PubMed     Abstract available
     
     
     
102. IBANEZ B, Latini R, Rossello X, Dominguez-Rodriguez A, et al
     Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.
     N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2504735.
     PubMed     Abstract available
     
     
     
103. TONET E, Raisi A, Zagnoni S, Chiaranda G, et al
     Multidomain Rehabilitation for Older Patients with Myocardial Infarction.
     N Engl J Med. 2025 Aug 29. doi: 10.1056/NEJMoa2502799.
     PubMed     Abstract available
     
     
     
104. MCGUIRE DK, David JP, Inzucchi SE
     Oral Semaglutide and Cardiovascular Outcomes. Reply.
     N Engl J Med. 2025;393:725.
     PubMed    
     
     
     
105. DOS SANTOS MCF, de Lima NN, Lima JG
     Oral Semaglutide and Cardiovascular Outcomes.
     N Engl J Med. 2025;393:724-725.
     PubMed    
     
     
     July 2025
106. MENSAH GA
     Estimates of Cardiovascular Risks and Benefits - When Knowing Is Not Enough.
     N Engl J Med. 2025;393:187-189.
     PubMed    
     
     
     June 2025
107. DAKIK HA
     Aspiration Thrombectomy for Coronary Stent Thrombosis.
     N Engl J Med. 2025;392:e52.
     PubMed    
     
     
     May 2025
108. JOLLY SS, d'Entremont MA, Mian R
     Colchicine and Spironolactone in Acute Myocardial Infarction. Reply.
     N Engl J Med. 2025;392:2075.
     PubMed    
     
     
     
109. JOLLY SS, d'Entremont MA, Lee SF
     Colchicine and Spironolactone in Acute Myocardial Infarction. Reply.
     N Engl J Med. 2025;392:2074-2075.
     PubMed    
     
     
     
110. GOLINO M, Van Tassell B, Abbate A
     Colchicine and Spironolactone in Acute Myocardial Infarction.
     N Engl J Med. 2025;392:2073-2074.
     PubMed    
     
     
     
111. KIDA Y
     Colchicine and Spironolactone in Acute Myocardial Infarction.
     N Engl J Med. 2025;392:2073.
     PubMed    
     
     
     
112. GU HQ, Jiang Y, Li H
     Colchicine and Spironolactone in Acute Myocardial Infarction.
     N Engl J Med. 2025;392:2072-2073.
     PubMed    
     
     
     
113. VAN TWIST DJL, Appelboom Y
     Colchicine and Spironolactone in Acute Myocardial Infarction.
     N Engl J Med. 2025;392:2072.
     PubMed    
     
     
     
114. STRIESSNIG J
     Colchicine and Spironolactone in Acute Myocardial Infarction.
     N Engl J Med. 2025;392:2071-2072.
     PubMed    
     
     
     
115. ZANNAD F
     Seeking Multiorgan Benefits with Cardiovascular-Kidney-Metabolic Drug Therapy.
     N Engl J Med. 2025;392:2061-2062.
     PubMed    
     
     
     
116. QIU Z, Li F, Sang H, Yuan G, et al
     Intravenous Tenecteplase before Thrombectomy in Stroke.
     N Engl J Med. 2025 May 21. doi: 10.1056/NEJMoa2503867.
     PubMed     Abstract available
     
     
     
117. NICHOLLS SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al
     Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
     N Engl J Med. 2025 May 7. doi: 10.1056/NEJMoa2415820.
     PubMed     Abstract available
     
     
     
118. RADER DJ
     Targeting Lipoprotein(a) - the Next Frontier in Cardiovascular Disease.
     N Engl J Med. 2025;392:1740-1742.
     PubMed    
     
     
     March 2025
119. MAGNUSSEN C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, et al
     Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
     N Engl J Med. 2025 Mar 30. doi: 10.1056/NEJMoa2415879.
     PubMed     Abstract available
     
     
     
120. MCGUIRE DK, Marx N, Mulvagh SL, Deanfield JE, et al
     Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
     N Engl J Med. 2025 Mar 29. doi: 10.1056/NEJMoa2501006.
     PubMed     Abstract available
     
     
     
121. KOTANIDIS CP, Maron DJ, Jernberg T
     Beta-Blocker Therapy after Acute Myocardial Infarction - To Block or Not to Block?
     N Engl J Med. 2025;392:1234-1236.
     PubMed    
     
     
     February 2025
122. RIDKER PM, Buring JE
     Biomarkers and 30-Year Cardiovascular Outcomes in Women. Reply.
     N Engl J Med. 2025;392:828.
     PubMed    
     
     
     
123. PEI C, Zhang W, Huang J
     Biomarkers and 30-Year Cardiovascular Outcomes in Women.
     N Engl J Med. 2025;392:828.
     PubMed    
     
     
     
124. GUI C, Huang Y
     Biomarkers and 30-Year Cardiovascular Outcomes in Women.
     N Engl J Med. 2025;392:827-828.
     PubMed    
     
     
     
125. CHO MS, Nam GB, Park DW
     Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease. Reply.
     N Engl J Med. 2025;392:826-827.
     PubMed    
     
     
     
126. SHIMAZU Y
     Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease.
     N Engl J Med. 2025;392:826.
     PubMed    
     
     
     
127. GREMMEL T
     Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease.
     N Engl J Med. 2025;392:826.
     PubMed    
     
     
     
128. KAWAI T, Williams WW, Elias N, Fishman JA, et al
     Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease.
     N Engl J Med. 2025 Feb 7. doi: 10.1056/NEJMoa2412747.
     PubMed     Abstract available
     
     
     January 2025
129. SILVAIN J, Vicaut E, Montalescot G
     Beta-Blockers after Myocardial Infarction. Reply.
     N Engl J Med. 2025;392:100-101.
     PubMed    
     
     
     
130. CHI KY, Nanna MG
     Beta-Blockers after Myocardial Infarction.
     N Engl J Med. 2025;392:99.
     PubMed    
     
     
     
131. GASOWSKI J, Perera I, Piotrowicz K
     Beta-Blockers after Myocardial Infarction.
     N Engl J Med. 2025;392:99.
     PubMed    
     
     
     
132. VAN VOLLENHOVEN RF
     Beta-Blockers after Myocardial Infarction.
     N Engl J Med. 2025;392:99.
     PubMed    
     
     
     December 2024
133. PURI R
     The Art and Science of Managing Stable Coronary Artery Disease in Patients Undergoing TAVI.
     N Engl J Med. 2024;391:2267-2268.
     PubMed    
     
     
     
134. SALEH Y, Rios S
     Spontaneous Coronary-Artery Dissection.
     N Engl J Med. 2024;391:e54.
     PubMed    
     
     
     November 2024
135. FIORELLA D, Monteith SJ, Hanel R, Atchie B, et al
     Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma.
     N Engl J Med. 2024 Nov 20. doi: 10.1056/NEJMoa2409845.
     PubMed     Abstract available
     
     
     
136. JOLLY SS, d'Entremont MA, Lee SF, Mian R, et al
     Colchicine in Acute Myocardial Infarction.
     N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMoa2405922.
     PubMed     Abstract available
     
     
     
137. JOLLY SS, d'Entremont MA, Pitt B, Lee SF, et al
     Routine Spironolactone in Acute Myocardial Infarction.
     N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMoa2405923.
     PubMed     Abstract available
     
     
     
138. RUBIN EJ, Leopold J, Morrissey S
     NEJM at AHA - Routine Spironolactone in Acute Myocardial Infarction.
     N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMe2414472.
     PubMed    
     
     
     
139. SAPP JL, Tang ASL, Parkash R, Stevenson WG, et al
     Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.
     N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2409501.
     PubMed     Abstract available
     
     
     October 2024
140. HEATON K, Zern EK, Spahillari A, Barrett CD, et al
     Case 34-2024: A 69-Year-Old Man with Dyspnea after Old Myocardial Infarction.
     N Engl J Med. 2024;391:1633-1641.
     PubMed    
     
     
     
141. ALKAISSI H, Nazari MA, Hadrava Vanova K, Uher O, et al
     Rapid Cardiovascular Response to Belzutifan in HIF2A-Mediated Paraganglioma.
     N Engl J Med. 2024;391:1552-1555.
     PubMed    
     
     
     
142. JERNBERG T
     Routine Beta-Blockers in Secondary Prevention - Approaching Retirement?
     N Engl J Med. 2024;391:1356-1357.
     PubMed    
     
     
     September 2024
143. HABIB M, Aronson D
     Electrocardiographic Findings in Diffuse Subendocardial Ischemia.
     N Engl J Med. 2024;391:e19.
     PubMed    
     
     
     
144. RUBIN EJ, Leopold J, Morrissey S
     NEJM at ESC - Invasive versus Conservative Strategy for Older Patients with Myocardial Infarction.
     N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2410900.
     PubMed    
     
     
     
145. KUNADIAN V, Mossop H, Shields C, Bardgett M, et al
     Invasive Treatment Strategy for Older Patients with Myocardial Infarction.
     N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407791.
     PubMed     Abstract available
     
     
     
146. RUBIN EJ, Leopold J, Morrissey S
     NEJM at ESC - Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
     N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2410903.
     PubMed    
     
     
     
147. LIP GYH
     Atrial Fibrillation and Stable Coronary Artery Disease.
     N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2409696.
     PubMed    
     
     
     
148. CHO MS, Kang DY, Ahn JM, Yun SC, et al
     Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
     N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407362.
     PubMed     Abstract available
     
     
     August 2024
149. RUBIN EJ, Leopold J, Morrissey S
     NEJM at ESC - Inflammation, Cholesterol, Lipoprotein(a) and 30-Year Cardiovascular Outcomes in Women.
     N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMe2410895.
     PubMed    
     
     
     
150. BLUMENTHAL RS, Martin SS
     Prevention of Cardiovascular Disease - Don't Stop Thinking about Tomorrow.
     N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMe2409080.
     PubMed    
     
     
     
151. RIDKER PM, Moorthy MV, Cook NR, Rifai N, et al
     Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women.
     N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2405182.
     PubMed     Abstract available
     
     
     
152. LONBORG J, Jabbari R, Sabbah M, Veien KT, et al
     PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation.
     N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2401513.
     PubMed     Abstract available
     
     
     
153. SILVAIN J, Cayla G, Ferrari E, Range G, et al
     Beta-Blocker Interruption or Continuation after Myocardial Infarction.
     N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMoa2404204.
     PubMed     Abstract available
     
     
     
154. RUBIN EJ, Leopold J, Morrissey S
     NEJM at ESC - Beta Blocker Interruption or Continuation with Prior Myocardial Infarction.
     N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMe2410891.
     PubMed    
     
     
     
155. MAHENDIRAN T, Collet C, De Bruyne B
     More on Coronary-Artery Autoregulation with Increasing Stenosis. Reply.
     N Engl J Med. 2024;391:671.
     PubMed    
     
     
     
156. YANG X, Wu M, Zhang G
     More on Coronary-Artery Autoregulation with Increasing Stenosis.
     N Engl J Med. 2024;391:670-671.
     PubMed    
     
     
     July 2024
157. BOHM F, James S
     FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction. Reply.
     N Engl J Med. 2024;391:288.
     PubMed    
     
     
     
158. LI P
     FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
     N Engl J Med. 2024;391:287-288.
     PubMed    
     
     
     
159. YNDIGEGN T, Hofmann R, Jernberg T
     Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. Reply.
     N Engl J Med. 2024;391:95.
     PubMed    
     
     
     
160. KOMAMURA K, Kobayashi K, Iwase M
     Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
     N Engl J Med. 2024;391:94-95.
     PubMed    
     
     
     
161. CLELAND JGF, McMurray JJV, Freemantle N
     Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
     N Engl J Med. 2024;391:94.
     PubMed    
     
     
     June 2024
162. MOLLER JE, Hassager C
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock. Reply.
     N Engl J Med. 2024;390:2328-2330.
     PubMed    
     
     
     
163. VON LEWINSKI D, Herold L, Toth GG
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:2328.
     PubMed    
     
     
     
164. BALDETTI L, Pieri M, Scandroglio AM
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:2328.
     PubMed    
     
     
     
165. ELKARYONI A, Hyder O, Saad M
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:2327.
     PubMed    
     
     
     
166. FROM AM
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:2327.
     PubMed    
     
     
     
167. MALLIDI J, Lotfi A
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:2326-2327.
     PubMed    
     
     
     
168. THIELE H, Desch S, Zeymer U
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:2325-2326.
     PubMed    
     
     
     
169. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
     Prevention of Cardiovascular Disease in Type 1 Diabetes. Reply.
     N Engl J Med. 2024;390:2227.
     PubMed    
     
     
     
170. MAAHS DM, Svensson J
     Prevention of Cardiovascular Disease in Type 1 Diabetes.
     N Engl J Med. 2024;390:2226-2227.
     PubMed    
     
     
     
171. WENSTEDT EFE, Vogt L
     Prevention of Cardiovascular Disease in Type 1 Diabetes.
     N Engl J Med. 2024;390:2226.
     PubMed    
     
     
     
172. LI S, Gu HQ, Li H, Wang X, et al
     Reteplase versus Alteplase for Acute Ischemic Stroke.
     N Engl J Med. 2024 Jun 14. doi: 10.1056/NEJMoa2400314.
     PubMed     Abstract available
     
     
     
173. XIONG Y, Campbell BCV, Schwamm LH, Meng X, et al
     Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.
     N Engl J Med. 2024 Jun 14. doi: 10.1056/NEJMoa2402980.
     PubMed     Abstract available
     
     
     
174. MAHENDIRAN T, Collet C, De Bruyne B
     Coronary-Artery Autoregulation with Increasing Stenosis.
     N Engl J Med. 2024;390:2030-2032.
     PubMed    
     
     
     May 2024
175. KING G, Hamilton GW
     Left Ventricular Thrombus after Anterior Myocardial Infarction.
     N Engl J Med. 2024;390:e50.
     PubMed    
     
     
     
176. NATARAJAN P
     Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease.
     N Engl J Med. 2024 May 29. doi: 10.1056/NEJMe2405647.
     PubMed    
     
     
     
177. ALBERS GW, Purdon B, Campbell BCV
     Tenecteplase for Stroke at 4.5 to 24 Hours. Reply.
     N Engl J Med. 2024;390:1729.
     PubMed    
     
     
     
178. GOYAL M, Bosshart SL, Ospel JM
     Tenecteplase for Stroke at 4.5 to 24 Hours.
     N Engl J Med. 2024;390:1729.
     PubMed    
     
     
     
179. GRINSPOON SK, Ribaudo HJ, Douglas PS
     Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection.
     N Engl J Med. 2024;390:1626-1628.
     PubMed    
     
     
     April 2024
180. STEG PG
     Routine Beta-Blockers in Secondary Prevention - On Injured Reserve.
     N Engl J Med. 2024;390:1434-1436.
     PubMed    
     
     
     
181. RAO SV
     Mechanical Circulatory Support in Cardiogenic Shock - Persistence and Progress.
     N Engl J Med. 2024;390:1436-1438.
     PubMed    
     
     
     
182. MOLLER JE, Engstrom T, Jensen LO, Eiskjaer H, et al
     Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:1382-1393.
     PubMed     Abstract available
     
     
     
183. BOHM F, Mogensen B, Engstrom T, Stankovic G, et al
     FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
     N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMoa2314149.
     PubMed     Abstract available
     
     
     
184. KUNADIAN V
     Role of Physiology in the Management of Nonculprit Lesions in Acute Coronary Syndrome.
     N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMe2403527.
     PubMed    
     
     
     
185. YNDIGEGN T, Lindahl B, Mars K, Alfredsson J, et al
     Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
     N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2401479.
     PubMed     Abstract available
     
     
     
186. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
     Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
     N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2402309.
     PubMed     Abstract available
     
     
     
187. GIBSON CM, Duffy D, Korjian S, Bahit MC, et al
     Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
     N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2400969.
     PubMed     Abstract available
     
     
     
188. ROULEAU J
     Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment.
     N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMe2402719.
     PubMed    
     
     
     
189. BUTLER J, Jones WS, Udell JA, Anker SD, et al
     Empagliflozin after Acute Myocardial Infarction.
     N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2314051.
     PubMed     Abstract available
     
     
     
190. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
     Prevention of Cardiovascular Disease in Type 1 Diabetes.
     N Engl J Med. 2024;390:1207-1217.
     PubMed    
     
     
     March 2024
191. WHITE HD
     A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
     N Engl J Med. 2024;390:10.
     PubMed    
     
     
     
192. AL-LAMEE RK, Rajkumar CA
     A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
     N Engl J Med. 2024;390:1151-1152.
     PubMed    
     
     
     
193. DURANTE A, Baiardo Redaelli M
     A Placebo-Controlled Trial of PCI for Stable Angina.
     N Engl J Med. 2024;390:1150-1151.
     PubMed    
     
     
     
194. SHERROD CF 4TH, O'Keefe EL, Ikemura N
     A Placebo-Controlled Trial of PCI for Stable Angina.
     N Engl J Med. 2024;390:1150.
     PubMed    
     
     
     
195. BESTERMANN WH JR
     A Placebo-Controlled Trial of PCI for Stable Angina.
     N Engl J Med. 2024;390:1149-1150.
     PubMed    
     
     
     
196. ROSWELL RO, Wong MP, Stefanescu Schmidt AC, Petranovic M, et al
     Case 8-2024: A 55-Year-Old Man with Cardiac Arrest, Cardiogenic Shock, and Hypoxemia.
     N Engl J Med. 2024;390:1030-1043.
     PubMed    
     
     
     
197. CARSON JL, Brooks MM, Hebert PC
     Transfusion Strategy in Myocardial Infarction and Anemia. Reply.
     N Engl J Med. 2024;390:961-962.
     PubMed    
     
     
     
198. KHAN MS, Spertus JA, Chan PS
     Transfusion Strategy in Myocardial Infarction and Anemia.
     N Engl J Med. 2024;390:960-961.
     PubMed    
     
     
     
199. CHAPALAIN X, Aubron C
     Transfusion Strategy in Myocardial Infarction and Anemia.
     N Engl J Med. 2024;390:960.
     PubMed    
     
     
     
200. MARFELLA R, Prattichizzo F, Sardu C, Fulgenzi G, et al
     Microplastics and Nanoplastics in Atheromas and Cardiovascular Events.
     N Engl J Med. 2024;390:900-910.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum